Combined use of high-sensitivity serological and virological HBV markers can make better in predicting the occurrence of HBV reactivation and to optimize prophylaxis duration in HBsAg-neg/anti-HBc-pos patients in the context of oncohematological diseases.

European Meeting on HIV & Hepatitis 2020

Ibalizumab shows in vitro activity against group A and group B HIV-2 clinical isolates

European Meeting on HIV & Hepatitis 2020

TDR surveillance and clinically relevant resistance in Spain: 2019 update

European Meeting on HIV & Hepatitis 2020

Prevalence of drug resistance mutations to rilpivirine and doravirine among NNRTI-experienced patients in Italy

European Meeting on HIV & Hepatitis 2020

HCV resistance associated variants following directly acting agent therapy failure- real life data from Poland

European Meeting on HIV & Hepatitis 2020

Absence of GS-6207 Phenotypic Resistance in HIV Gag Cleavage Site Mutants, Patient Isolates With Gag Polymorphisms, and Isolates With Resistance To Existing Drug Classes

European Meeting on HIV & Hepatitis 2020

Prevalence of transmitted resistance mutations to rilpivirine and doravirine in treatment-naive patients in a large clinical and resistance database

European Meeting on HIV & Hepatitis 2020

Genotyping and treatment issues with unusual 1e and 1g HCV subtypes from African subjects: report of two cases.

European Meeting on HIV & Hepatitis 2020

Susceptibility to bNAbs of transmitted HIV variants among recent infections in France

European Meeting on HIV & Hepatitis 2020

Baseline Hepatitis C Virus NS5A Resistance-Associated Polymorphisms in Patients with and without HIV coinfection in Mexico

European Meeting on HIV & Hepatitis 2020

Substantial clustered transmission of the acute hepatitis C among HIV co-infected men-who-have-sex-with-men (MSM)

European Meeting on HIV & Hepatitis 2020

Ibalizumab shows in vitro activity against group A and group B HIV-2 clinical isolates

European Meeting on HIV & Hepatitis 2020

Antiretroviral resistance in patients with multiple treatment failure in a low-middle income setting

European Meeting on HIV & Hepatitis 2020

Late presentation and HIV drug resistance in patients followed in Portugal between 1984-2017

European Meeting on HIV & Hepatitis 2020

Prevalence and Correlates of Pre-Treatment HIV Drug Resistance among HIV-Infected in the Republic of Belarus

European Meeting on HIV & Hepatitis 2020

Genetic characteristic of HIV-1 in patients with treatment failure in Kyrgyzstan in 2017-2018.

European Meeting on HIV & Hepatitis 2020

Case of detection of drug resistance mutations hepatitis C virus to the direct-acting antivirals

European Meeting on HIV & Hepatitis 2020

Prevalence of pretreatment HIV-1 drug resistance among treatment-naïve patients in the Russian Federation, 2014–2018

European Meeting on HIV & Hepatitis 2020

The HBV treatment outcome to cART in HBV/HIV co-Infected patients who failed lamivudine containing regimens

European Meeting on HIV & Hepatitis 2020

Hepatotoxicity and the hepatic panel analysis among HIV-positive Ukrainian patients receiving efaverentz and dolutegravir-containing modes

European Meeting on HIV & Hepatitis 2020

Feasibility and efficacy assessment of hepatitis B vaccination among adult PLWH and vulnerable population in Vinnytsia region, Ukraine

European Meeting on HIV & Hepatitis 2020

Natural course of hepatitis C virus infection: which factors affect spontaneous clearance of HCV among the Ukrainian population?

European Meeting on HIV & Hepatitis 2020

Achieving the goals of the Fast-Track 90-90-90 strategy in the context of an anti-terrorist operation

European Meeting on HIV & Hepatitis 2020

Effectiveness and tolerability of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in HIV-1-infected adult patients in German routine clinical practice – 12-month results of the BICSTaR cohort

European Meeting on HIV & Hepatitis 2020